Examples of using Data on safety in English and their translations into German
{-}
-
Medicine
-
Official
-
Colloquial
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Arzerra is not recommended for use in children below 18 years due to insufficient data on safety and/or efficacy.
PREZISTA is not recommended for use in children and adolescents because there are no data on safety, efficacy and pharmacokinetics.
Children and adolescents Bondronat is not recommended for patients below age 18 years due to insufficient data on safety and efficacy.
Ebixa is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Post marketing data on safety and tolerability across all pazopanib clinical trials
ALIMTA is not recommended for use in children below 18 years of age due to insufficient data on safety and efficacy.
adolescents below 18 years due to insufficient data on safety and efficacy.
Agenerase is not recommended in children below 4 years due to lack of data on safety and efficacy see section 5.2.
adolescents below 18 years due to insufficient data on safety and efficacy.
Stalevo is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
RoActemra is not recommended for use in children below 18 years of age due to insufficient data on safety and efficacy.
AUBAGIO should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy.
adolescents due to a lack of data on safety and efficacy.
CELSENTRI is not recommended for use in children due to lack of data on safety, efficacy and pharmacokinetics see section 5.2.
Revatio solution for injection is not recommended for use in children below 18 years due to insufficient data on safety and efficacy.
adolescents due to lack of data on safety and efficacy.
This ensures that relevant data on safety has to be presented
Alli should not be used in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.
Paediatric patients OPTISON is not recommended for use in children below 18 years due to lack of data on safety and efficacy.
Fuzeon is not recommended for use in children below age 6 due to insufficient data on safety and efficacy see section 5.2.